# A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)

> **NCT07083388** · PHASE1 · RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 52 (estimated)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg
- **DRUG:** Dapagliflozin 10 mg
- **DRUG:** Pioglitazone 30 mg
- **DRUG:** Metformin HCl 1000 mg

## Key facts

- **NCT ID:** NCT07083388
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-03
- **Primary completion:** 2026-07-03
- **Final completion:** 2026-07-03
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07083388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07083388, "A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07083388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*